Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PAVmed Inc. stock logo
PAVM
PAVmed
$0.60
+1.0%
$0.65
$0.55
$1.90
$10.21M1.06135,585 shs19,874 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$47.71
+5.9%
$44.86
$17.02
$70.26
$155.94M0.1935,964 shs27,791 shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$31.65
-0.2%
$30.34
$5.17
$39.50
$270.79M1.24145,744 shs21,863 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$4.86
+3.4%
$4.70
$4.01
$9.33
$76.63M1.29191,513 shs36,647 shs
Beyond Air, Inc. stock logo
XAIR
Beyond Air
$0.18
+0.7%
$0.19
$0.15
$0.68
$15.46M0.221.54 million shs702,165 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PAVmed Inc. stock logo
PAVM
PAVmed
0.00%-0.50%-2.66%+0.34%-15.68%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.00%+6.31%+15.66%-6.27%+178.52%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
0.00%+5.68%+17.22%+3.20%+3,164,999,900.00%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
0.00%0.00%-0.61%+8.97%-4.14%
Beyond Air, Inc. stock logo
XAIR
Beyond Air
0.00%+11.88%-4.79%-25.91%-69.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
PAVmed Inc. stock logo
PAVM
PAVmed
3.958 of 5 stars
3.55.00.04.30.00.01.9
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
2.4928 of 5 stars
2.52.00.00.02.81.71.9
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
1.8795 of 5 stars
3.63.00.00.01.80.00.0
Beyond Air, Inc. stock logo
XAIR
Beyond Air
3.9175 of 5 stars
3.73.00.03.51.10.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PAVmed Inc. stock logo
PAVM
PAVmed
3.00
Buy$19.003,082.58% Upside
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
3.00
Buy$56.0017.38% Upside
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
0.00
N/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.25
Buy$11.67140.05% Upside
Beyond Air, Inc. stock logo
XAIR
Beyond Air
3.33
Buy$1.50737.99% Upside

Current Analyst Ratings Breakdown

Latest PAVM, XAIR, SNWV, SRTS, and PDEX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
PAVmed Inc. stock logo
PAVM
PAVmed
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.50 ➝ $19.00
5/27/2025
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$54.00 ➝ $56.00
5/19/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
4/21/2025
PAVmed Inc. stock logo
PAVM
PAVmed
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$19.00 ➝ $19.50
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PAVmed Inc. stock logo
PAVM
PAVmed
$2.99M3.41N/AN/A($0.92) per share-0.65
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$53.84M2.89$0.96 per share49.94$9.03 per share5.28
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$32.63M8.30N/AN/A($1.49) per share-21.24
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$41.81M1.91$0.45 per share10.79$3.41 per share1.43
Beyond Air, Inc. stock logo
XAIR
Beyond Air
$3.70M4.18N/AN/A$0.17 per share1.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PAVmed Inc. stock logo
PAVM
PAVmed
$39.79M$0.710.84N/AN/A3,711.54%N/A-42.29%8/12/2025 (Estimated)
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$2.13M$2.8017.0423.16N/A14.61%29.08%16.19%9/4/2025 (Estimated)
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$31.37M-$4.56N/AN/A-89.86%N/A-145.76%N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M$0.1048.6021.13N/A4.56%3.34%3.00%8/6/2025 (Estimated)
Beyond Air, Inc. stock logo
XAIR
Beyond Air
-$46.62M-$0.79N/AN/AN/A-1,258.46%-233.96%-113.92%8/5/2025 (Estimated)

Latest PAVM, XAIR, SNWV, SRTS, and PDEX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
Beyond Air, Inc. stock logo
XAIR
Beyond Air
-$0.14-$0.09+$0.05-$0.09$1.39 million$1.15 million
5/15/2025Q1 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.04-$0.16-$0.20-$0.16$7.23 million$8.34 million
5/9/2025Q1 2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A-$0.66N/A-$0.66N/A$9.34 million
5/1/2025Q3 2025
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$0.47$0.98+$0.51$0.98$17.70 million$17.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
Beyond Air, Inc. stock logo
XAIR
Beyond Air
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.37
0.37
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.28
2.73
1.45
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A
0.40
0.28
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
8.06
5.74
Beyond Air, Inc. stock logo
XAIR
Beyond Air
0.64
3.20
2.72

Institutional Ownership

CompanyInstitutional Ownership
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
42.53%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%
Beyond Air, Inc. stock logo
XAIR
Beyond Air
31.50%

Insider Ownership

CompanyInsider Ownership
PAVmed Inc. stock logo
PAVM
PAVmed
7.30%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
47.50%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
36.60%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
8.90%
Beyond Air, Inc. stock logo
XAIR
Beyond Air
19.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
PAVmed Inc. stock logo
PAVM
PAVmed
9017.09 million15.85 millionOptionable
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
1403.26 million1.71 millionNot Optionable
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
408.56 million5.43 millionN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.44 million14.98 millionOptionable
Beyond Air, Inc. stock logo
XAIR
Beyond Air
7086.37 million69.61 millionOptionable

Recent News About These Companies

Beyond Air Inc.
Beyond Air granted U.S. patent for gaseous nitric oxide delivery
Beyond Air Gets Patent for Lung Infection Treatment

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVmed stock logo

PAVmed NASDAQ:PAVM

$0.60 +0.01 (+1.02%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$0.60 0.00 (0.00%)
As of 07/3/2025 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Pro-Dex stock logo

Pro-Dex NASDAQ:PDEX

$47.71 +2.66 (+5.90%)
As of 07/3/2025 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Sanuwave Health stock logo

Sanuwave Health NASDAQ:SNWV

$31.65 -0.07 (-0.22%)
As of 07/3/2025 01:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$4.86 +0.16 (+3.40%)
As of 07/3/2025 02:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

Beyond Air stock logo

Beyond Air NASDAQ:XAIR

$0.18 +0.00 (+0.67%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$0.18 0.00 (-0.56%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.